Matthew Arnold Marx

USPTO Granted Patents = 26 (Patent Applications = 22)

CIPO Patents = 3 (Patent Applications = 10)

EPO Patents = 8 (Patent Applications = 31)

Average Co-Inventor Count = 6.2

ph-index = 5

Forward Citations = 79(Granted Patents)

Company Filing History:

26 out of 38

Mirati Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12421253 - Tetrahydropyridopyrimidine pan-KRas inhibitors (2025-09-23),

2. 12421228 - Naphthyridine derivatives as PRC2 inhibitors (2025-09-23),

3. 12398154 - Azaquinazoline pan-KRas inhibitors (2025-08-26),

4. 12371435 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2025-07-29),

5. 12304915 - SOS1 inhibitors (2025-05-20),

6. 12252493 - Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer (2025-03-18),

7. 11999753 - Tetrahydropyridopyrimidine pan-KRas inhibitors (2024-06-04),

8. 11964989 - KRas G12D inhibitors (2024-04-23),

9. 11932633 - KRas G12C inhibitors (2024-03-19),

10. 11702418 - SOS1 inhibitors (2023-07-18),

11. 11548888 - KRas G12C inhibitors (2023-01-10),

12. 11492351 - MTA-cooperative PRMT5 inhibitors (2022-11-08),

13. 11485738 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-11-01),

14. 11479551 - MTA-cooperative PRMT5 inhibitors (2022-10-25),

15. 11453683 - KRas G12D inhibitors (2022-09-27),

Title: Exploring the Innovations of Matthew Arnold Marx in Cancer Research

Introduction

Matthew Arnold Marx, based in San Diego, CA, is a prominent inventor with a significant contribution to cancer research through his innovative developments. With a remarkable portfolio of 20 patents, his work focuses primarily on the discovery of new compounds that target specific mutations in the KRas gene, which are crucial in various types of cancer.

Latest Patents

Two of his latest patents highlight the cutting-edge nature of his research. The first patent is for "Tetrahydropyridopyrimidine pan-KRas inhibitors," which relates to compounds that inhibit various KRas mutations, including KRas wild type, KRas G12A, G12C, G12D, and more. This invention includes pharmaceutical compositions that incorporate these compounds and methods for their application in treating cancer. The second patent concerns "KRas G12D inhibitors," focusing on compounds designed to inhibit the activity of the KRas G12D mutation specifically. This discovery holds promise for developing effective treatments against cancer linked to this mutation.

Career Highlights

Matthew Arnold Marx's career encompasses significant roles in leading biotechnology companies. He has worked at Mirati Therapeutics and Array Biopharma, where he harnessed his expertise to advance therapeutic solutions in oncology. His dedication to research and innovation has positioned him as a key figure in the fight against cancer.

Collaborations

Throughout his career, Matthew has collaborated with notable professionals in the industry, including James Gail Christensen and Aaron Craig Burns. These partnerships have facilitated the exchange of ideas and have contributed to the development of groundbreaking therapies aimed at tackling cancer's challenges.

Conclusion

With his extensive patent portfolio and significant research contributions, Matthew Arnold Marx continues to influence the field of cancer treatment. His innovative compounds targeting KRas mutations reflect a promising avenue for future therapeutic developments, highlighting the importance of his work in improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.